Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

DNA Damage can Stall the Cell Cycle

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Restarting Stalled Replication Forks

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Application of machine learning to create a prediction model for the need of aggressive nutritional intervention during head & neck cancer radiotherapy.

Clinical nutrition ESPEN·2025

Same author

A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities.

Nature chemical biology·2025

Same author

Development of a Novel Amplifiable System to Quantify Hydrogen Peroxide in Living Cells.

Journal of the American Chemical Society·2024

Same author

Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy.

Journal of medicinal chemistry·2024

Same author

Selective Smurf1 E3 ligase inhibitors that prevent transthiolation.

bioRxiv : the preprint server for biology·2023

Same author

Elongation Factor P Modulates the Incorporation of Structurally Diverse Noncanonical Amino Acids into <i>Escherichia coli</i> Dihydrofolate Reductase.

Journal of the American Chemical Society·2023

Search research articles

Related Experiment Video

Updated: Jul 5, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

Development of a PROTAC Targeting Chk1.

Sandipan Roy Chowdhury¹, Patrick Chuong¹, Victoria E Mgbemena²

¹Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Health 2, 4349 Martin Luther King Boulevard, Houston, Texas, 77204.

Biorxiv : the Preprint Server for Biology

|January 23, 2024

Summary

Researchers developed novel Chk1 degraders by linking kinase binders to thalidomide. PROTAC-2 effectively reduced Chk1 protein levels in cancer cells, paving the way for improved Chk1-targeted therapies.

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

Related Experiment Videos

Last Updated: Jul 5, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

Area of Science:

Medicinal Chemistry
Molecular Biology
Cancer Therapeutics

Background:

Checkpoint kinase 1 (Chk1) is a critical regulator of cell cycle progression and DNA damage response.
Dysregulation of Chk1 is implicated in various cancers, making it a promising therapeutic target.
Targeting Chk1 for degradation offers a novel therapeutic strategy beyond traditional kinase inhibition.

Approach:

Designed and synthesized a series of Chk1 degraders by conjugating a promiscuous kinase binder with thalidomide.
Utilized a proteolysis-targeting chimera (PROTAC) approach to induce targeted protein degradation.
Evaluated the efficacy of synthesized degraders in reducing Chk1 protein levels in A375 melanoma cells.

Key Points:

PROTAC-2, a novel Chk1 degrader, demonstrated significant reduction of Chk1 protein levels in a concentration-dependent manner.
The developed degraders showcase the potential of PROTAC technology for targeting Chk1.
This study provides a foundation for developing more selective and potent Chk1 degraders.

Conclusions:

The synthesized Chk1 degraders, including PROTAC-2, represent a promising new class of molecules for cancer therapy.
These PROTACs offer a viable strategy for targeting Chk1, potentially overcoming resistance mechanisms associated with kinase inhibitors.
Further development of these Chk1 degraders could lead to novel therapeutic agents with enhanced efficacy and selectivity.